The global hepatitis B market size is predicted to increase from USD 4.78 billion in 2024, grow to USD 4.94 billion in 2025, and is anticipated to reach around USD 6.65 billion by 2034, poised to grow at a CAGR of 3.36% between 2024 and 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Hepatitis B Market
5.1. COVID-19 Landscape: Hepatitis B Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Hepatitis B Market, By Type
8.1. Hepatitis B Market, by Type, 2024-2034
8.1.1 Acute
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Chronic
8.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Hepatitis B Market, By Treatment
9.1. Hepatitis B Market, by Treatment, 2024-2034
9.1.1. Immune Modulator Drugs
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Antiviral Drugs
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Vaccine
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Surgery (Liver Transplant)
9.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Hepatitis B Market, By Distribution Channel
10.1. Hepatitis B Market, by March, 2024-2034
10.1.1. Hospital & Retail Pharmacies
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Online Pharmacies
10.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Hepatitis B Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.1.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.2.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.3.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.4.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.5.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel(2021-2034)
Chapter 12. Company Profiles
12.1. Accord Healthcare Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Apotex Corp.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Arbutus Biopharma
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Arrowhead Pharma
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Aurobindo Pharma Limited
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bristol-Myers Squibb Company
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Gilead Sciences, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. GlaxoSmithKline
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Lupin Pharmaceuticals, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Merck & Co., Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample